The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.

Saved in:
Bibliographic Details
Title: The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Authors: Kumar, Divya P.1 divyapkumar@jssuni.edu.in, Caffrey, Rebecca2, Marioneaux, Jonathon2, Santhekadur, Prasanna K.1, Bhat, Madhavi2, Alonso, Cristina3, Koduru, Srinivas V.4, Philip, Binu5, Jain, Mukul R.5, Giri, Suresh R.5, Bedossa, Pierre6, Sanyal, Arun J.7 arun.sanyal@vcuhealth.org
Source: Scientific Reports. 6/9/2020, Vol. 10 Issue 1, p1-14. 14p.
Database: Academic Search Ultimate
Description
ISSN:20452322
DOI:10.1038/s41598-020-66458-z